Executive readout · one minute
What the filings say
- 8-K earnings release · filed Nov 12, 2026
- Parabilis Medicines reported a 72.2% objective response rate at the 32-week landmark among evaluable desmoid-tumor patients receiving a starting dose of ≥450 mg; $1.1 billion in cash, cash equivalents and marketable securities is expected to fund operations into 2030.
- 10-Q report · filed Nov 12, 2026
- Net loss widened to $44.5 million for the three months ended September 30, 2026, from $33.5 million a year earlier. Research and development expense rose to $45.6 million, mainly from higher external costs for zolucatetide. Cash, cash equivalents and marketable securities totaled $1,072.9 million at September 30, 2026, which the company expects to fund operations into 2030.
The audio replay and transcript follow the call.